相关实验视频

Updated: Sep 16, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

第一线治疗:时间有限的威尼托克拉克斯双重治疗

Jennifer Huang¹, Mazyar Shadman¹

¹Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA; Division of Medicine, University of Washington, Seattle, WA, USA.

Hematology/oncology clinics of North America

|July 11, 2025

概括

威尼托克拉克斯组合显示,比B细胞恶性瘤的化疗免疫疗法更有生存益处. 确定最佳的B细胞白血病/淋巴瘤2抑制剂 (BCL2i) 和布鲁顿氨酸激酶抑制剂 (BTKi) 组合对于一线治疗至关重要.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

维内托克拉克斯是一种B细胞白血病/淋巴瘤2抑制剂 (BCL2i),与抗CD20单克隆抗体或共布鲁顿氨酸激酶抑制剂 (BTKi) 相结合,已显示出改善的生存结果.
目前B细胞白血病和淋巴瘤的治疗模式通常涉及化疗免疫疗法.
在治疗这些血液性恶性瘤中,BCL2i的最佳组合伙伴仍然是积极研究的领域.

研究的目的:

与传统化疗免疫疗法相比,评估基于venetoclax的组合疗法的疗效.
确定BCL2i和BTKi在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的第一线治疗中最有效的组合.
根据B细胞恶性瘤的最佳治疗策略,为临床决策提供信息.

主要方法:

综述了检查venetoclax在组合治疗方案中的研究.
对无进展生存率和整体生存率数据的比较分析.
考虑新兴的第二代布鲁顿氨酸激酶抑制剂 (BTKi).

主要成果:

威尼托克拉克斯 (Venetoclax) 组合显示,比化疗免疫疗法更有利于无进展的生存率.
在一些基于venetoclax的治疗方案的研究中观察到总体生存益处.
对B细胞白血病/淋巴瘤2抑制剂 (BCL2i) 的最佳组合合作伙伴仍在调查中.

结论:

基于Venetoclax的组合代表了对B细胞白血病和淋巴瘤的有前途的治疗方法.
需要进一步的研究来确定最有效的BCL2i和BTKi组合用于一线治疗.
第二代BTK的发展可能会进一步完善治疗策略.

关键词:

慢性淋巴细胞白血病慢性淋巴细胞白血病双重治疗是一种双重疗法.时间有限的疗法.威尼托克拉克斯 (Venetoclax) 是一个属于威尼托克拉克斯的地区.

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications